Cargando…

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study

INTRODUCTION: The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ(1–42)) measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and cognitively normal (CN) subjects across different studies. Therefore, identifying novel proteins to characterize symptomatic AD sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Yuk Yee, Toledo, Jon B., Nefedov, Alexey, Polikar, Robi, Raghavan, Nandini, Xie, Sharon X., Farnum, Michael, Schultz, Tim, Baek, Young, Van Deerlin, Vivianna M., Hu, William T., Holtzman, David M., Fagan, Anne M., Perrin, Richard J., Grossman, Murray, Soares, Holly D., Kling, Mitchel A., Mailman, Matthew, Arnold, Steven E., Narayan, Vaibhav A., Lee, Virginia M-Y., Shaw, Leslie M., Baker, David, Wittenberg, Gayle M., Trojanowski, John Q., Wang, Li-San
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672388/ https://www.ncbi.nlm.nih.gov/pubmed/26693175 http://dx.doi.org/10.1016/j.dadm.2015.06.008

Ejemplares similares

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
por: Bai, Xue, et al.
Publicado: (2020)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
por: Henkens, Michiel T.H.M., et al.
Publicado: (2020)

The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy
por: Raafs, Anne G., et al.
Publicado: (2021)

Benefits and obstacles of telemetric ICP monitoring
por: Oertel, Joachim M. K., et al.
Publicado: (2021)

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Test-Retest Reliability of Diffusion Tensor Imaging in Huntington’s Disease
por: Cole, James H., et al.
Publicado: (2014)

Knowledge-Driven Approaches to Create the MTox700+ Metabolite Panel for Predicting Toxicity
por: Sostare, Elena, et al.
Publicado: (2022)

Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment
por: Hatherell, Sarah, et al.
Publicado: (2020)

Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy
por: Tolosana, Jose María, et al.
Publicado: (2010)

The diagnostic value of the pulsatility curve to predict shunt responsiveness in patients with idiopathic normal pressure hydrocephalus
por: van Bilsen, M. W. T., et al.
Publicado: (2022)

Compliance of the cerebrospinal space: comparison of three methods
por: Kazimierska, Agnieszka, et al.
Publicado: (2021)

Complications of external cerebrospinal fluid drainage in aneurysmal subarachnoid haemorrhage
por: Arts, Sebastian, et al.
Publicado: (2021)

Upper limb dysfunction and activities in daily living in idiopathic normal pressure hydrocephalus
por: Sirkka, Jani, et al.
Publicado: (2021)

Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
por: Bahls, Martin, et al.
Publicado: (2019)

Non-adjustable gravitational valves or adjustable valves in the treatment of hydrocephalus after aneurysmal subarachnoid hemorrhage patients?
por: Arts, Sebastian, et al.
Publicado: (2022)

Cerebrospinal fluid dynamics in idiopathic intracranial hypertension: a literature review and validation of contemporary findings
por: Kaipainen, Aku L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bs79noc8enj9dp4qlrjct9rud4